TIMP1 and neoplasm: Here, the 2-AG increase results from the inhibition of MAGL and leads to a reduction in the angiogenic capacities of endothelial cells in the tumor microenvironment via a CB1-dependent pathway, with increased TIMP-1 release from lung tumor cells being causative.